

# AtCor Medical SphygmoCor®

Essential for hypertension management.



ASX release

12 July 2017

## Secures \$0.8 million new pharmaceutical trial contracts

- 3 trials signed in last 30 days
- Majority of value to be recognised in FY2018

AtCor Medical (ASX: ACG), the developer and marketer of SphygmoCor® for advanced hypertension management, today announced that it has signed three new contracts to supply SphygmoCor systems and clinical trial support services. The new deals are with major international pharmaceutical companies and their combined value is \$0.8 million.

The clinical trials, for two existing clients and one new client, will be conducted in the USA, Europe and Japan and run for 12-17 months. Two studies are Phase II trials which if successful are expected to open a larger opportunity for AtCor Medical when the trials progress to Phase III.

Duncan Ross, CEO of AtCor Medical said: "We are very pleased to have secured these contracts which supports AtCor's diversification into new therapeutic areas. They include a trial in the acute coronary syndrome field, which is a condition brought on by the sudden reduction of blood to the heart, and a trial in the heart failure field. Heart failure is a chronic and increasingly costly disease, and a growing focus for AtCor's SphygmoCor technology in the clinic<sup>1</sup>. SphygmoCor has been specified for additional heart failure trials in FY2018 with other companies, and negotiations are underway.

SphygmoCor has also recently been used in drug trials for inflammatory disorders and type 2 diabetes, further expanding our addressable market.

### About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, doctors' offices, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

<sup>1</sup> Wohlfarht et al, Aortic Waveform Analysis Individualizes Treatment in Heart Failure, Circulation: Heart Failure. 2017;10:e003516

<http://atcormedical.com/wp-content/uploads/2017/02/ACG0401.pdf>

SphygmoCor® is a registered trademark of AtCor Medical Pty Ltd and its related parties.

For personal use only

*For further information, please contact:*

Duncan Ross . AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley . AtCor Medical CFO  
+61 (2) 8815 8811

*Media enquiries to:*

Ashley Rambukwella . Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)

For personal use only